**Table S1.** Socio-demographic characteristics in the samples with and without JTC task data.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **JTC task missing**  **N= 51** | **JTC task**  **N= 360** |
| **Status**  **(N, %)** | HC | 10 (19.6%) | 57 (15.8%) |
|  | CHR-NT | 34 (66.7%) | 245 (68.1%) |
|  | CHR-T | 7 (13.7%) | 58 (16.1%) |
| **Gender**  **(N, %)** | Male | 32 (62.7%) | 187 (51.9%) |
|  | Female | 19 (37.3%) | 173 (48.1%) |
| **Ethnicity**  **(N, %)** | White | 34 (66.7%) | 254 (70.8%) |
| **Age in years (mean, SD)** |  | 22.0 (6.3) | 22.5 (4.5) |
| **IQ (mean, SD)** |  | 102.1 (20.2) | 100.8 (17.8) |
| **GAF disability** |  | 62.45 (14.5) | 60.0 (16.3) |

JTC: Jumping to Conclusion; HC: Healthy Controls; CHR-NT Clinical High Risk for Psychosis who did not make transition to psychosis; CHR-T Clinical High Risk who made transition; IQ: Intelligence Quotient; GAF: Global Assessment of Functioning.

**Table S2.** Draws to decision (DTD, mean (SD) by groups

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **HC** | **CHR-NT** | **CHR-T** |  |
| **Baseline** | 7.02 (4.29) | 6.43 (4.67) | 6.91 (4.84) | F(2,359)= 0.52, p=0.59 |
| **1-year follow-up** | 8.07 (3.81) | 7.59 (4.53) | 7.27 (5.24) | F(2,162)= 0.18, p=0.37 |
| **2-year follow-up** | 7.17 (3.85) | 6.68 (4.21) | 5.36 (6.25) | F(2, 124)= 0.7, p=0.12 |

HC: Healthy Controls; CHR-NT Clinical High Risk for Psychosis who did not make transition to psychosis; CHR-T Clinical High Risk who made transition.

**Table S3.** Clinical symptoms according to baseline JTC

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HC (N= 57)** | | **CHT-NT (N= 245)** | | **CHT-T (N= 58)** | |
|  | No JTC | JTC | No JTC | JTC | No JTC | JTC |
| **SANS affective flattening (mean, SD)** | 0.005 (0.04) | 0 | 0.53 (0.63) | 0.65 (0.72) | 0.86 (0.97) | 0.81 (0.89) |
| **SANS alogia (mean, SD)** | 0.01 (0.07) | 0 | 0.33 (0.57) | 0.52 (0.62) | 0.5 (.67) | 0.55 (0.7) |
| **SANS avolition (mean, SD)** | 0.01 (0.08) | 0 | 1.2 (0.97) | 1.4 (0.93) | 1.45 (0.96) | 1.23 (0.98) |
| **SANS anhedonia (mean, SD)** | 0.04 (0.14) | 0 | 1.44 (1.06) | 1.53 (1.11) | 1.81 (1.22) | 1.57 (1.09) |
| **SANS attention (mean, SD)** | 0 | 0.07 (0.21) | 0.48 (0.78) | 0.57 (0.78) | 0.68 (0.84) | 1.12 (1.14) |
| **MADRS (mean, SD)** | 1.48 (3.37) | 0\* | 18.48 (8.95) | 18.6 (9.3) | 20.64 (9.24) | 18.07 (11.12) |
| **CAARMS positive (mean, SD)** | 0.72 (1.6) | 0.3 (0.95) | 9.93 (4.2) | 9.76 (3.75) | 10.58 (3.44) | 10.53 (3.85) |

\*p<0.05 after adjusting for multiple comparisons

HC: Healthy Controls; CHR-NT Clinical High Risk for Psychosis who did not make transition to psychosis; CHR-T Clinical High Risk who made transition; SANS: The Scale for Assessment of Negative Symptoms; MADRS: the Montgomery-Asberg Depression Scale; CAARMS: The Comprehensive Assessment of At-Risk Mental State.